The proangiogenic activity of bFGF, which is a heparin-binding growth factor, can be inhibited by different strategies, such as the reduction of bFGF production by tumour cells, the modulation of the release of active bFGF from the ECM, and the modification of the FGF-FGFR recognition [33, 34]. Here, HDGF is linked to neoplasm.